BioPharma Today

Latest News from "The Pink Sheet" DAILY - Dendreon Set To Ship Provenge Soon

Dendreon Set To Ship Provenge Within A Week

Demand expected to exceed supply as company builds manufacturing capacity.   read more

Coming in Wednesday's "The Pink Sheet" DAILY - Legal Updates for Merck, AstraZeneca

Hospira has voluntarily suspended shipments of two drugs – Propofol, an anesthesia, and Liposyn, a fat emulsion for low birth weight babies – to address manufacturing concerns raised by FDA in a recent warning letter.

Latest News from "The Pink Sheet" DAILY - Novartis' Sandoz Unit Makes Respiratory Push

Pharmerging Markets Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

IMS forecasts a 5 percent to 8 percent growth of global pharmaceutical sales annually through 2014. read_more_>

Coming In Tuesday's "The Pink Sheet" DAILY - Merck Pipeline News and FDA Advisory Committee Mtgs. On Tap

Merck unveils integrated late-stage pipeline, including 40 Phase II and Phase III medicines of which eight are in the areas of cardiovascular or infectious disease.

Latest News from "The Pink Sheet" DAILY - Salix's Xifaxan Advisory Panel Review

Salix's Xifaxan Draws Ambivalent Recommendation From Advisory Panel

Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies. read_more_>

Latest News from "The Pink Sheet" DAILY -- Merck Unveils Gardasil Data

Merck Looks To Mid-June FDA Decision On Expanded Use Of Gardasil To Older Women

Company unveils data at European conference supporting use in women ages 27 through 45; data was sent to FDA late last year.   read more

Latest News from "The Pink Sheet" DAILY

Notes From J.P. Morgan: Daschle Disses DTC

A collection of dispatches from the J.P. Morgan health care conference in San Francisco.   read more

The Long Shadow of HillaryCare

Full article reprinted from The RPM Report July 28, 2009

A common theme for reform advocates in 2009 is avoiding the mistakes that doomed the Clinton health care reform effort 15 years ago. The biggest lesson of all is that the consequences of failure would be critical to the Obama Administration. Read more...

European Biosimilars’ Market Performance Mirrors US Legislative Progress: Slow but Steady

Article reprinted from The RPM Report May 19, 2009

Biosimilars haven’t had a huge impact in Europe—yet. Sponsors and analysts expect that to change over time. Will the US market parallel the European experience? Read on...

Special Edition with Expanded Coverage on the Swine Flu Outbreak from "The Pink Sheet" and Inteleos

May 5, 2009

In the face of the current swine flu outbreak, Elsevier Business Intelligence remains on top of the latest news, providing you with all the insight and analysis you need to know on how our industry is affected.

Article titles include:

~Vaccine For Swine Flu Faces Multiple Decision Points By Government

~Flu Headlines Challenge New FDA Heads
~FDA Chief Scientist Goodman Spearheads Agency Response to Swine Flu

Read this exclusive coverage now...